ICR | August 2018 | Drug combination gives ‘exciting’ results in ovarian and lung cancer in early trial
The results of an early clinical trial suggest that a combination of chemotherapy and a new drug could be used to provide treatment for patients with advanced ovarian and lung cancer, where other treatments had failed.
Scientists from The Institute of Cancer Research, London (ICR), and The Royal Marsden NHS Foundation Trust, decided to test vistusertib, which inhibits the activation of a specific molecule in ovarian cancer cells, to determine if the drug combination was safe for patients, the dosage and its efficacy. The combination of targeted drug vistusertib along with paclitaxel chemotherapy caused tumours of over 50 per cent of patients with ovarian cancer and over 33 % with lung cancer to shrink, and stopped patients’ cancers from growing for almost six months.
This far exceeds what is expected with standard treatments in patients with advanced disease who have already had, and have now become resistant to, standard treatment (Source: ICR).
Read the full news release from The Institute for Cancer Research Drug combination gives ‘exciting’ results in ovarian and lung cancer in early trial
In the news: